THE BEHAVIORAL-EFFECTS OF MK-801 INJECTED INTO NUCLEUS-ACCUMBENS AND CAUDATE-PUTAMEN OF RATS

Basit Öğe Kaydı
dc.authoridUlugol, Ahmet/0000-0003-4643-1124
dc.authoridKaradag, Cetin Hakan/0000-0002-4763-986X
dc.authorwosidUlugol, Ahmet/V-9665-2019
dc.authorwosidKaradag, Cetin Hakan/H-4899-2013
dc.contributor.authorALKHATIB, I
dc.contributor.authorKARADAG, HC
dc.contributor.authorULUGOL, A
dc.date.accessioned2024-06-12T11:08:39Z
dc.date.available2024-06-12T11:08:39Z
dc.date.issued1995
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIn this study, we investigated the behavioral effects of MK-801 (1-20 mu g) injected into the posterior parts of nucleus accumbens (ACC) and caudate-putamen (CP) in rats. Interactions of diazepam (DZP, 10 mu g), haloperidol (HPD, 2 mu g), and scopolamine (SCOP, 10 mu g) with 20 mu g of MK-801 were also studied. All injections were done in 2 mu l. In ACC, MK-801 increased locomotion, rearing, and head shakes. The effect of MK-801 especially at 20 mu g was accompanied by a motor syndrome: head weaves, circling, body rolls, and ataxia. DZP nonsignificantly reduced the locomotion but it significantly (p < 0.05) reduced head shakes, weaves, circling, and body rolls produced by MK-801. HPD reduced grooming and head shakes. SCOP potentiated MK-801 hyperlocomotion, whereas it decreased body rolls, head shakes, and weaves. In CP, MK-801 increased locomotion, but less than in ACC (p < 0.05). The effect of MK-801 was significantly increased by SCOP. MK-801 also increased grooming (reduced by HPD and increased by SCOP) and at 5-20 mu g induced oral movements that were decreased by HPD. These results indicate that the posterior part of ACC is involved in MK-801 hyperlocomotion and motor syndromes, whereas CP is involved in mediating grooming and oral movements. Blockade of the muscarinic cholinergic receptors seems to facilitate hyperlocomotion and decrease head shakes produced by MK-801. Mechanisms influenced by DZP and HPD appear to be involved in motor syndrome and oral movement, respectively, induced by MK-801, but not in hyperlocomotion.en_US
dc.identifier.doi10.1016/0091-3057(95)00158-S
dc.identifier.endpage730en_US
dc.identifier.issn0091-3057
dc.identifier.issue4en_US
dc.identifier.pmid8587911en_US
dc.identifier.scopus2-s2.0-0028801413en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage723en_US
dc.identifier.urihttps://doi.org/10.1016/0091-3057(95)00158-S
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22502
dc.identifier.volume52en_US
dc.identifier.wosWOS:A1995TF40800012en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofPharmacology Biochemistry And Behavioren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMK-801en_US
dc.subjectNUCLEUS ACCUMBENSen_US
dc.subjectCAUDATE-PUTAMENen_US
dc.subjectLOCOMOTIONen_US
dc.subjectMOTOR SYNDROMEen_US
dc.subjectNoncompetitive Nmda Antagonisten_US
dc.subjectMonoamine-Depleted Miceen_US
dc.subjectMethyl-D-Aspartateen_US
dc.subjectHypermotility Responseen_US
dc.subjectReceptor Antagonisten_US
dc.subjectPrefrontal Cortexen_US
dc.subjectBasal Gangliaen_US
dc.subjectDopamineen_US
dc.subjectDizocilpineen_US
dc.subjectAgonistsen_US
dc.titleTHE BEHAVIORAL-EFFECTS OF MK-801 INJECTED INTO NUCLEUS-ACCUMBENS AND CAUDATE-PUTAMEN OF RATSen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu